menu
    • menu
    [{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"OSE-230","moa":"ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ AbbVie Inc"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"OSE-230","moa":"ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ AbbVie Inc"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"OSE-230","moa":"ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OSE Immunotherapeutics SA

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            OSE Immunotherapeutics SA

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OSE-230

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : $713.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            OSE Global License for Novel Antibody for Chronic Inflammation Becomes Effective

                            Details : Under the licensing agreement, AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.

                            Product Name : OSE-230

                            Product Type : Antibody

                            Upfront Cash : $48.0 million

                            April 16, 2024

                            Lead Product(s) : OSE-230

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : $713.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OSE Immunotherapeutics SA

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            OSE Immunotherapeutics SA

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OSE-230

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : $713.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            AbbVie and OSE Immunotherapeutics Partner for Chronic Inflammation Therapy

                            Details : The partnership aims to focus on the development of OSE-230, which is an agonist antibody against ChemR23. It is being evaluated in the preclinical trial studies for chronic and severe inflammation.

                            Product Name : OSE-230

                            Product Type : Antibody

                            Upfront Cash : $48.0 million

                            February 28, 2024

                            Lead Product(s) : OSE-230

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : $713.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            OSE Immunotherapeutics SA

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            OSE Immunotherapeutics SA

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OSE-230

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution o...

                            Details : The poster presentation highlights efficacy results for OSE-230 in chronic inflammatory preclinical models and ex vivo human models.inflammatory preclinical models and ex vivo human models.

                            Product Name : OSE-230

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 30, 2020

                            Lead Product(s) : OSE-230

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth